RF EMerge

A Resource for Innovators

On October 6, 2021, Voyager Therapeutics and Pfizer entered into a license option agreement, which allows Pfizer to exercise options to license Voyager’s adeno-associated virus (AAV) capsids for gene therapies.

Voyager is a Massachusetts-based company developing AAV-based gene therapies.  The
Continue Reading Pfizer and Voyager Agree to Develop Neurologic and Cardiovascular Gene Therapies Valued at up to $630 Million

On September 13, 2021, Regenxbio, a Maryland biotech company, and AbbVie announced that they have entered an agreement to develop and commercialize a potential gene therapy drug developed by Regenxbio for treating age-related macular degeneration (wet AMD), diabetic retinopathy, and
Continue Reading Abbvie and Regenexbio Agree to Develop and Commercialize Eye Disease Gene Therapy

Caribou Biosciences, Inc., a Berkeley, California-based CRISPR genome-editing biopharmaceutical company, raised $304M in an initial public offering, one of the most lucrative IPOs in gene-editing. In June 2021, Gene editing biotech Verve raised $267M in IPO proceeds and later added
Continue Reading Caribou Biosciences Raises $304M in Potentially the Largest Gene Editing IPO

On July 13, 2021, Prime Medicine, a Massachusetts biotech company developing next generation gene editing technology, emerged from stealth mode with $315 million in financing.  The financing includes a $115 million Series A and a $200 million series B investment.
Continue Reading Prime Medicine Emerges with $315 Million to Develop Next Generation Gene Editing Platform

In today’s world, e-commerce and online visibility are sine qua non for success. Businesses are willing to invest considerable sums to boost their online presence and maximize sales. Because of this digitalization of business, domain names acquired incredible value. And
Continue Reading Domain Name “Trolls”: The Trademark Trial and Appeal Board May Have Offered A Way Out